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 Previous studies on macrolide resistance in Campylobacter were primarily 
focused on the isolates from various origins using in vitro systems. In this study, both in 
vitro and in vivo experiments were conducted to examine the development, stability, and 
genetic basis of macrolide resistance in C. jejuni. All in vitro and in vivo selected EryR 
mutants were derived from the same parent strain C. jejuni NCTC 11168. To determine if 
long-term exposure of low-level EryR C. jejuni to low-dose tylosin selects for high-level 
EryR mutants (MIC > 512 µg/ml), two low-level EryR mutants (MIC = 32 or 64 µg/ml) 
were used to inoculate chickens at 15 days of age in two independent experiments. Total 
and EryR C. jejuni populations in swabs collected at different time points were 
determined by differential plating and MIC test. The in vitro stability was tested by 
repeated subculturing of EryR mutants in Ery-free broth medium. The in vivo stability 
was tested by inoculating 3-day-old chickens (12-13 birds/group) receiving non-
medicated feed with EryR mutants and collecting cloacal swabs from each chickens at 12, 
22, 38, and 47 days of age. Total and EryR C. jejuni populations in culture (after 10, 20 
and 33 passages) or swab were determined by differential plating and MIC test. Genomic 
DNA from each of 63 selected EryR mutants was used for PCR amplification and 
sequence analysis of 23S rRNA gene and ribosomal proteins L4 and L22. Mutation in 
CmeABC multidrug efflux pump was transferred to EryR strains to determine the role of 
CmeABC efflux pump in Ery resistance. Chicken studies showed that the length of 
exposure time to subtherapeutic level of tylosin is not a sole factor contributing to the 
emergence of highly EryR Campylobacter. Prolonged exposure of low-level EryR C. 
jejuni (MIC = 32 or 64 µg/ml) to tylosin did not select for highly EryR mutants. The low-
  v
level Ery resistance (MIC = 32μg/ml) was stable after 10 passages in vitro but majority of 
C. jejuni were sensitive to Ery after 20 passages. The instability of low-level Ery 
resistance was also observed in chickens as early as 9 days postinoculation and EryR 
mutants were rarely isolated 35 days postinoculation. However, high-level Ery resistance 
(MIC > 512μg/ml) displayed remarkably stability in vitro and in vivo. All high-level EryR 
mutants selected in vivo displayed the A2074G mutation in 23S rRNA gene, distinct from 
the specific mutation (A2074C) observed in all highly EryR mutants selected in vitro. No 
mutations were observed in ribosomal proteins L4 for all in vitro selected EryR mutants 
but specific mutations in L4 (G74D or G57D) were widely found in low level EryR 
mutants selected in vivo (Ery MIC = 8-64 μg/ml). Insertion of three amino acids TSH at 
position 98 in L22 was only observed in mutants selected in vitro with Ery MIC ranging 
from 32-512 μg/ml. The CmeABC efflux pump worked synergistically with other 
mechanisms to confer Ery resistance in C. jejuni. Together, these findings indicated that 
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1. REVIEW OF LITERATURE 
 
 
Animal antibiotic use and antibiotic resistance in foodborne pathogens 
 The intensity of food animal production systems presents opportunities for the 
introduction and spread of disease. Therefore, antibiotics are often administered to food 
animals to improve health and growth performance. According to a recent estimate, 24.6 
million pounds, over half of the antibiotics produced each year in the US, are used in 
agriculture (Mellon et al. 2001). In animal agriculture, antibiotics can be administered 
whenever symptoms appear in a few animals (therapeutic treatment), or in anticipation of 
symptoms (prophylactic treatment). In addition, some antibiotics are widely administered 
as feed additives at sub-therapeutic levels in food animals to enhance growth rates and 
improve feed efficiency (growth promotion) (Dibner & Richards 2005; Frost & 
Woolcock 1991). The antibiotics used for growth promotion are also called ‘antibiotic 
growth promoter’ (AGP) and have been used worldwide in food animals more than 50 
years (Dibner & Richards 2005; Frost & Woolcock 1991). To date, many antimicrobials 
with different mechanisms of action have been used as AGPs in the food animal industry 
(Chapman & Johnson 2002; Frost & Woolcock 1991; Gaskins et al. 2002).  In poultry, 
antibiotics including bacitracin, virginiamycin, tylosin, bambermycins, and lincomycin 
have been used as AGPs with no withdrawal period required (Animal Health Institute 
2005; Chapman & Johnson 2002; Gaskins et al. 2002).  Usually a combination of 
different AGPs instead of single AGP is used in feeds during a complete production cycle 
to maximize the efficacy of AGPs.  In poultry, bacitracin was used more frequently than 
other antibiotics in the starter and grower feed while virginiamycin was used more 
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frequently in finisher feed (Chapman & Johnson 2002). 
 Foodborne human pathogens are increasingly resistant to antimicrobial agents, 
compromising the effectiveness of currently available drugs for treating human illness 
(White et al. 2002). Development of  antimicrobial resistance in bacteria may also 
directly affect human disease development through various mechanisms such as 
increased virulence (Barza 2002). One of the driving forces behind the progression of 
antibiotic resistance is the selective pressure exerted by the widespread  use of 
antimicrobial agents in food animal production (Teuber 1999; Wegener 2003a). 
Inappropriate use of antibiotics in agriculture can result in increased antibiotic-resistant 
organisms, not only among pathogens but also among commensal microflora of animals 
that can be subsequently transferred to human via the food chain (McEwen & Fedorka-
Cray 2002; Wegener et al. 1997). This possibility is particularly strong with foodborne 
human pathogens, such as Campylobacter and Salmonella, which are primarily 
transmitted from animals to humans via contaminated food (Slutsker et al. 1998). Since 
person-to-person transmission rarely occurs with these foodborne human pathogens in 
developed countries, the primary sources of human infections with resistant bacteria are 
likely from food producing animals (White et al. 2002). Therefore, food animals can 
serve as a reservoir for resistant bacteria (Witte 2000) and/or resistant gene clusters 
which can then enter the environment and be transmitted to human pathogens (Heuer et 
al. 2006; Lipsitch et al. 2002). 
 Therapeutic use of antibiotics has been demonstrated to select drug resistant 
human pathogens in food animals (Aarestrup 2005; Angulo et al. 2004). Recent studies 
have shown an increase in Campylobacter resistance to fluoroquinolones (FQs), a drug of 
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choice for treating human infections, following the approval of FQs for treatment of food 
animal infections in 1995 (Gaudreau & Gilbert 2003; Hein et al. 2003; Nachamkin et al. 
2002). Laboratories studies have demonstrated the emergence of FQ-resistant 
Campylobacter in experimental chickens (Luo et al. 2003; McDermott et al. 2002) and 
pigs (Delsol et al. 2004) treated with FQ antibiotics. Strikingly, FQ treatment of chickens 
infected with FQ-sensitive Campylobacter promoted the emergence of FQ-resistant 
Campylobacter mutants; almost all Campylobacter shed by chickens were FQ-resistant 
after just 3 days of enrofloxacin treatment (Luo et al. 2003).  These findings highlight the 
need for the prudent use of FQ antibiotics.  Consequently, to prevent and control 
Campylobacter resistance to FQs, the FDA issued a ban on the use of Baytril (a FQ used 
in animal) in poultry in 2005 ( www.fda.gov/bbs/topics/news/2005/new01212.html). 
Evidence of an association between the use of gentamicin in food animals and gentamicin 
resistant Enterococci isolated from food of animal origin and humans was also recently 
reported. Resistant rates of more than 30% were reported on swine and poultry farms in 
Michigan, Wisconsin, and Indiana (Hershberger et al. 2005). The same gentamicin 
resistance genes present in Enterococci isolated from food animals were also found in 
isolates from food products of the same animal species (Donabedian et al. 2003). 
 Although it has been widely believed that the low dosages of AGP used for 
growth promotion are an unquantified hazard, long-term use of AGP in feed could exert 
great selection pressure for developing antibiotic-resistant bacteria (WHO, 2004) 
Epidemiological studies have strongly linked AGP application to the emergence of 
antibiotic-resistant bacteria, consequently posing a serious threat to public health 
(Wegener 2003a). For example, vancomycin resistant Enterococci have long been 
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associated with the use of avoparcin (a vancomycin analogue) as growth promoters in 
food animals (Bager et al. 1997; Wegener et al. 1999) Thus, Denmark banned all AGPs 
in 1998 and European Union member nations banned all AGPs in January 2006 (Dibner 
& Richards 2005; Wegener 2003b). However, in Europe, it has been observed that the 
levels of antibiotic resistance in animals and food, and consequently in humans, have 
been markedly reduced after the termination of AGP use (Wegener 2003b). In 
Switzerland, Boerlin et al. (2001) reported a clear decrease in Enterococci resistance to 
macrolides, lincosamides, and tetracycline after the ban of AGPs. In Tawain, the 
occurrence of vancomycin resistant Enterococci decreased in association with a ban on 
avoparcin as a feed additive on chicken farms (Lauderdale et al. 2007). Other studies also 
noted a decrease in vancomycin- resistant enterococci following the ban on avoparcin as 
a growth promoter, although the resistant strains did not disappear completely  
(Heuer et al. 2002; Borgen et al. 2001). Furthermore, several studies have also noted a 
reduction of  vancomycin resistant Enterococci in food-animal products and humans 
following  AGP ban in food animals (Klare et al. 1999; van den Bogaard et al. 2000; 
Witte 2000; Bager et al. 1999; Pantosti et al. 1999). Together, these findings provide 
compelling evidence for the role of AGPs in selecting resistant bacteria. Using 
experimental chicken model system, Lin et al. (2007) demonstrated that long-term use of 
a macrolide as a growth promoter selects for the emergence of erythromycin-resistant 
Campylobacter in animal reservoirs.  However, chickens subjected to single or multiple 
treatments with therapeutic dose of macrolide did not select for erythromycin-resistant 
Campylobacter (Lin et al. 2007).  
There is a worldwide trend of limiting AGP use in food animals (Dibner & 
  5
Richards 2005).  Although there has been little regulatory activity regarding AGP use in 
the United States, consumer pressure, market limitations, and export restrictions are 
pressuring commerce to withdraw AGPs from market (Dibner & Richards 2005). For 
example, KFC and McDonalds have claimed that they do not accept chicken meat grown 
using AGP with similar structure to the antibiotics used in humans in 2002 and 2005, 
respectively (Dibner & Richards 2005b).  
  
Campylobacter colonization in poultry 
 Campylobacter species are the most common cause of human gastrointestinal 
enteritis worldwide, accounting for 2.5 million cases each year in the United States 
(Friedman et al. 2000). Each year in the United States, 1.5 to 8 billion dollars in medical 
and production costs are attributed to Campylobacter infections (Buzby et al. 1997). 
Human Campylobacter infections are characterized by abdominal pain, watery or bloody 
diarrhea lasting a few days, and also fever, headache, nausea, and vomiting (Skirrow & 
Blaser 2000). The diarrhea typically lasts a few days. Although complications are rare, 
infection with Campylobacter can lead to Guillain- Barré syndrome an acute autoimmune 
disease affecting the peripheral nervous system that can result in respiratory compromise 
and death (Nachamkin et al. 1998).  Human Campylobacter illness is caused primarily by 
C. jejuni and secondarily by C. coli. Both Campylobacter species are closely related and 
require microaerophilic conditions (e.g. 5% O2, 10%CO2, and 85% N2) and elevated 
temperature (42 oC) for optimal growth. 
Although Campylobacter widely colonizes wild and domestic animals, poultry are 
considered the major reservoir of Campylobacter (Nesbit et al. 2001). Campylobacter is 
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highly prevalent in poultry and most human infections have been linked to consumption 
of undercooked poultry products or other food contaminated by these products (Allos 
2001). Other sources of human contamination include raw milk, undercooked beef or 
pork, and house pets (Corry & Atabay 2001). Interestingly, chickens mainly harbor C. 
jejuni, while turkeys tend to have more C. coli. Despite wide prevalence of 
Campylobacter in poultry, this organisms does not cause clinical signs of infection in 
poultry host under natural conditions (Newell & Fearnley 2003; Sahin et al. 2002). 
 Although prevalence estimates of Campylobacter vary, recent studies showed that 
80- 100% of broiler flocks in the US were contaminated with C. jejuni (Croft et al. 2007; 
Jacobs- Reitsma 1997; Stern et al. 2001b). Campylobacter is highly prevalent in organic, 
free-range, and conventional poultry production systems (Avrain et al. 2003; Heuer et al. 
2001; Luangtongkum et al. 2006; Luangtongkum et al. 2006), indicating that different 
production systems are equally vulnerable to invasion by this organism. The seasonality 
of Campylobacter infections, with a peak in the summer months, is also well documented 
(Evans & Sayers 2000; Sahin et al. 2002; Wedderkopp et al. 2000; Wedderkopp et al. 
2001; Newell & Wagenaar 2000).  
 The prevalence of Campylobacter in broiler flocks depends on the age of the birds 
(Evans & Sayers 2000; Newell & Fearnley 2003). In commercial conditions, 
Campylobacter is rarely detected in broilers less than 2- 3 weeks of age (Stern et al. 
2001a; Evans & Sayers 2000), although experimental inoculation of newly hatched 
chicks with Campylobacter can establish colonization successfully (Sahin et al. 2003b; 
Young et al. 1999). The reasons for this lag phase are unknown but might be attributed to 
multiple factors, such as presence of  maternal antibodies, antibiotic feed additives, 
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intestinal development, and intestinal microbial flora (Newell & Wagenaar 2000; Sahin et 
al. 2003b). 
 Although Campylobacter can be isolated from most intestinal sites of broiler 
chickens, it is mainly found in the cecal and cloacal crypts where it does not adhere to 
epithelial cells but is found in the mucous layer (Achen et al. 1998; Beery et al. 1988). 
While more than one strain of Campylobacter has been isolated from the same flock 
(Hiett et al. 2002b), individual chickens are rarely infected with more than one strain 
(Korolik et al. 1998). Experimental inoculation of chickens has shown that colonization 
rate can be influenced by dose of inoculum and route of challenge (Sahin et al. 2002). 
 Once the first bird in a flock becomes colonized, infection spreads to the entire 
flock in just a few days. This rapid spread of Campylobacter throughout the flock is 
likely a result of fecal-oral transmission, compounded by communal water and feed (Lee 
& Newell 2006). In broiler chickens, colonization persists for the lifetime of the animal 
that is usually less than 47 days, consequently leading to carcass contamination at the 
slaughter facility.  
 Although the sources of infection of poultry flocks are still unclear, horizontal 
transmission (transmission within a population) is considered the most likely mechanism 
(Sahin et al. 2002). Some potential sources include feed, water, and carryover from 
previous flocks (Newell & Fearnley 2003). Campylobacter also exists in the environment 
surrounding the broiler house and could be transferred into the house by wildlife species, 
houseflies, insects, equipment, and farm workers (Sahin et al. 2002). However, molecular 
typing of Campylobacter isolates from various sources including broilers, houses, 
humans, and the environment surrounding the broiler house did not clearly identify  the 
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sources of Campylobacter (Nesbit et al. 2001; Petersen et al. 2001a). Campylobacter is 
generally unable to persist in feed or water due to the stringent growing conditions 
(Jacobs- Reitsma 2000; Van De Giessen et al. 1998). Litter is also a potential but unlikely 
source of transmission (Stern et al. 2001b). Vertical transmission, although unlikely, has 
been suggested as a source of Campylobacter infection in broiler flocks. The 2-3 week 
lag phase presents evidence against vertical transmission. Also, broiler flocks are often 
infected with different strains than the corresponding breeder flocks (Petersen et al. 
2001b). Campylobacter has not been found in hatcheries or young hatchlings, and 
isolation from eggs has also proven difficult (Hiett et al. 2002a; Sahin et al. 2003a). 
 
Antibiotic resistance in Campylobacter 
Most human Campylobacter infections are self-limited and treated with fluid 
replacement (Allos 2001). However, antimicrobial treatment is often necessary for severe, 
prolonged, or systemic infections, or infections in immunocompromised patients 
(Engberg et al. 2001). In the US and other developed countries, Campylobacter isolates 
resistant to multiple drugs have been cultured from clinical and food samples (Boonmar 
et al. 2007; Gallay et al. 2007; Moore et al. 2005). Campylobacter isolates are 
increasingly resistant to FQs and macrolides, the major drugs of choice for treating 
human campylobacteriosis (Engberg 2006; Friedman et al. 2000; Moore et al. 2005; 
Smith et al. 2002; van den Bogaard et al. 2000). Campylobacter could also acquire 
resistance to other antibiotics such as tetracycline, β lactam, chloramphenicol, and 
aminoglycosides (Trieber & Taylor 2000). Campylobacter species display intrinsic 
resistance to rifampin and trimethoprim (Trieber & Taylor 2000). Thus, these two 
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antibiotics are included as selective agents in Campylobacter- specific growth 
supplement (SR0117E; Oxoid). Campylobacter develops three general mechanisms of 
antibiotic resistance: 1) inactivation of antibiotic itself (e.g. acetylation of 
chloramphenicol) 2) target site alteration ( e.g. mutations in ribosome affecting macrolide 
binding) 3) active drug efflux (e.g. CmeABC multidrug efflux pump) (Trieber & Taylor 
2000).  
Fluoroquinolones inhibit the activity of DNA gyrase and/ or DNA topoisomerase 
IV in bacteria (Drlica & Zhao 1997). There are two general mechanisms for 
Campylobacter resistance to FQs; which include modification of DNA gyrase and active 
efflux (Luo et al. 2003; Zhang et al. 2003). Specific mutations such as Asp-90-Asn and 
Thr-86-Lys in gyrase A were linked to FQ resistance in C. jejuni (Luo et al. 2003; Zhang 
et al. 2003). Unlike other bacteria, acquisition of high-level FQ resistance in 
Campylobacter does not require stepwise accumulation of point mutations in gyrA. 
Instead, a single step mutation in gyrA can create clinically relevant levels of resistance 
to FQs (Luo et al. 2003; Zhang et al. 2003). The simplicity of the gyrA-mediated 
resistance mechanism may facilitate the rapid emergence of FQ-resistant Campylobacter 
in response to FQ treatment (Zhang et al. 2003). It is still not clear why C. jejuni displays 
a hypermutable phenotype and FQ- resistant mutants emerge rapidly in infected chickens 
under the selective pressure of FQ antibiotics. A recent study indicated that the adaptive 
gene expression in Campylobacter may contribute to the rapid emergence of FQ-resistant 
mutants (Han & Zhang 2007). A multidrug efflux pump, named CmeABC, in 
Campylobacter contributes to both intrinsic and acquired FQ resistance in clinical 
isolates (Lin et al. 2002; Luo et al. 2003; Zhang et al. 2003). CmeABC is constitutively 
  10
expressed in Campylobacter and is essential for maintaining high-level FQ resistance. 
However, over-expression of CmeABC is not required for conferring the resistance, 
which distinguishes Campylobacter from other Gram-negative bacteria. Increasing 
resistance of Campylobacter isolates to FQs is associated with FQ usage in animals 
(Aarestrup & Wegener 1999; Nielsen et al. 2006; Smith et al. 2002). Regarding in vivo 
development of FQ resistance in Campylobacter, recent studies using chicken and pig 
models showed that FQ treatment has resulted in rapid emergence of FQ-resistant 
Campylobacter isolates (Delsol et al. 2004; McDermott et al. 2002; Luo et al. 2003). 
Particularly, Luo et al. (2003) noticed that after just 3 days of treatment with enrofloxacin 
(a quinolone antibiotic), 100% of Campylobacter shed by chickens were FQ-resistant. FQ 
resistance in Campylobacter has been shown to be stable even after treatment has stopped 
(McDermott et al. 2002; Luo et al. 2005).  
Increased Campylobacter resistance to FQs has resulted in a decrease of FQ usage 
in clinics. Erythromycin (a macrolide antibiotic) has become the best and a major choice 
for treating human Campylobacter infections recently (Nachamkin et al. 2000).  However, 
an increase in Campylobacter resistance to macrolides in human and animal isolates has 
been documented recently, arising more rapidly in developed countries (Gibreel & Taylor 
2006). More detailed information regarding macrolide resistance in Campylobacter is 
described below. 
 
Macrolide resistance in Campylobacter 
Macrolide antibiotics are the metabolic products of Steptomyces spp., which 
inhibit bacterial protein synthesis by binding to the 50S subunit of ribosome (Walsh 
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2003). This class of antibiotics including erythromycin, tylosin, spiramycin, tilmicosin, 
roxithromycin are approved for both growth promotion and therapeutic purpose in animal 
agriculture in the US (Mcewen & Fedorka-Cray 2002).   
 The use of macrolides in food animals has been associated with resistance in 
Campylobacter and presents opportunity for resistant isolates to reach humans via direct 
or indirect contact with contaminated food products (Aarestrup 2000; Gibreel & Taylor 
2006). The reported macrolide resistance rates vary with Campylobacter species and the 
animal hosts.  Campylobacter coli usually has higher macrolide resistance rates than C. 
jejuni, regardless of the source of isolation (Aarestrup & Engberg 2001; Engberg et al. 
2001; Kim et al. 2006). Likewise, pigs and turkeys tend to harbor higher numbers of 
macrolide resistant Campylobacter than other animal species. For example, in a study 
involving human, chicken, and pig isolates, C. coli was more resistant to Ery and 
ciprofloxacin than C. jejuni (Gallay et al. 2007). C. coli isolated from retail raw meats 
also showed higher rates of resistance to Ery and ciprofloxacin (Ge et al. 2003).  In 
Denmark, withdrawal of tylosin from swine feed additives significantly reduced EryR 
Campylobacter in pigs (Boerlin et al. 2001). A study examining EryR Campylobacter 
from broilers in France, before and after the growth promoter ban (1998), found no 
difference in resistance rates in C. jejuni, while a higher number of resistant C. coli were 
isolated after the ban. It is possible that the sample period was too close to the ban to 
detect true differences (Desmonts et al. 2004).  A high prevalence of Campylobacter has 
been shown in poultry from both organic and conventional production operations, while 
Campylobacter isolated from conventional poultry operations had significantly higher 
resistance rates to FQs, Ery, clindamycin, kanamycin, tetracycline, and ampicillin than 
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Campylobacter isolated from organically raised poultry (Luangtongkum et al. 2006). 
While EryR Campylobacter have been isolated from organically and intensively reared 
retail poultry, the isolates with the highest Ery MIC values were from intensively reared 
retail poultry (Soonthornchaikul et al. 2006). These observations suggest that different 
production practices influence the frequency of macrolide-resistant Campylobacter in 
animal reservoirs.   
 Direct experimental information supporting the relevance of macrolide use in 
food animals with emergence of macrolide resistant Campylobacter is very limited. A 
recent study found that long-term exposure of chickens to tylosin as a growth promoter 
selected for EryR Campylobacter mutants, while short-term (therapeutic) exposure did 
not (Lin et al. 2007). In this study, chickens experimentally infected with a macrolide-
sensitive Campylobacter strain were exposed to single or multiple therapeutic treatments 
of tylosin in water or exposed to tylosin in feed as a growth promoter. However, EryR 
mutants were not isolated from chickens receiving therapeutic tylosin treatment. In 
contrast, EryR mutants were isolated from chickens after 17 days of exposure to tylosin 
supplemented in feed as a growth promoter. In another recent study, Berrang et al (2007) 
isolated Campylobacter from carcasses of chickens that received feed supplemented with 
tylosin or unmedicated feed. Although the feed treatment did not affect actual numbers of 
Campylobacter on carcasses after washing, carcasses from chickens fed tylosin in feed as 
a growth promoter were found to harbor EryR Campylobacter, while carcasses from 
chickens fed unmedicated feed were not. The information from these studies suggests 
that use of tylosin as a growth promoter in feed results in EryR Campylobacter. 
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Mechanisms of macrolide resistance in Campylobacter 
Macrolide antibiotics inhibit bacterial growth by binding to the ribosome, 
inhibiting protein synthesis by causing premature dissociation of the growing peptidyl 
tRNA (Corcoran et al. 2006; Franceschi et al. 2004).  Macrolide resistance in bacteria is 
attributed to many mechanisms including target modifications (e.g. methylation of 23S 
rDNA, point mutations in 23S rDNA, and mutations in ribosomal proteins), and drug 
efflux (Gibreel & Taylor 2006). In Campylobacter, methylation of 23S rDNA is not 
reported to confer macrolide resistance. Modifications of the ribosomal target site (e.g. 
23S rDNA and ribosomal proteins L4 and L22) and active efflux (e.g. CmeABC efflux 
pump) are major mechanisms conferring macrolide resistance in Campylobacter. (Gibreel 
& Taylor 2006; Lin et al. 2002; Payot et al. 2006; Franceschi et al. 2004).  
Resistance in C. coli and C. jejuni has been associated with mutations in domain 
V of the 23S rRNA gene (Engberg et al. 2001; Gibreel & Taylor 2006; Mamelli et al. 
2005). These point mutations within the 23S rRNA gene occur at base position 2074 
(A2074C, A2074G, or A2074T) or 2075 (A2075G or A2075C), or both (which 
correspond to positions 2058 and 2059, respectively, in E. coli) (Gibreel et al. 2005; 
Jensen & Aarestrup 2001). There are three copies of the 23S rRNA gene in C. jejuni and 
C. coli (Parkhill et al. 2000) and wild-type and mutant copies can both be present in a 
single macrolide-resistant mutant (Gibreel et al. 2005). The most common mutation in 
macrolide-resistant Campylobacter is A2075G, which is associated with high-level 
erythromycin resistance (Gibreel & Taylor 2006). The A2074G mutation also confers 
high-level resistance but was thought to negatively affect the fitness of the organism, and 
was relatively unstable (Gibreel et al. 2005). Recently, all high- level erythromycin-
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resistant Campylobacter mutants selected in vivo displayed the A2074G mutation in the 
23S rRNA gene (Lin et al. 2007).  
Mutations in ribosomal proteins L4 and L22 have been reported to be associated 
with Ery resistance in Campylobacter (Corcoran et al. 2006). Gibreel et al (2005) did not 
find significant macrolide resistance-associated alterations in either L4 or L22 protein 
from five erythromycin-resistant clinical isolates. However, the involvement of some 
modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in 
Campylobacter has recently been demonstrated. A G74D mutation in protein L4 and 
insertions in protein L22 (ins86ARAR and ins98TSH) contributed to macrolide resistance 
(Cagliero et al. 2006b). Further investigations of modifications in these proteins are 
necessary to determine the exact effects of specific mutations on resistance. 
The CmeABC efflux pump has been well documented as the major drug efflux 
pump in Campylobacter (Lin et al. 2002; Luo et al. 2003). This pump has action against 
a variety of compounds (Gibreel & Taylor 2006). In the presence of efflux pump 
inhibitor, Campylobacter isolates displayed increased susceptibility to bile salts and 
reduced colonization in chickens (Lin et al. 2003; Lin & Martinez 2006). CmeABC 
efflux pump could play an important role in conferring macrolide resistance in 
Campylobacter (Cagliero et al. 2006b; Lin et al. 2002; Payot et al. 2004). Inhibition of 
the efflux pump has resulted in increased susceptibility to macrolides (Cagliero et al. 
2006b; Cagliero et al. 2006a; Corcoran et al. 2006; Lin et al. 2007; Payot et al. 2004), 
reducing both intrinsic and acquired resistance. Mamelli et al. noticed that low-level 
macrolide resistant isolates were susceptible to efflux pump inhibitor. The antibiotic- 
susceptible wild-type strain also showed increased susceptibility upon inhibition of the 
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efflux pump (Mamelli et al. 2005). The CmeABC efflux pump works in synergy with 
mutations in 23S rRNA and inactivation of the pump has resulted in increased 
susceptibility of high-level and low-level resistant human, pig, and poultry 
Campylobacter isolates to erythomycin (Cagliero et al. 2005; Lin et al. 2002, 2007).  
 
Fitness and stability of antibiotic resistant Campylobacter 
 The ecological fitness and stability of the antimicrobial resistance is a key 
parameter influencing the incidence, transmission, and persistence of antibiotic resistant 
bacteria in humans and in animal reservoirs (Andersson 2006). Acquiring drug resistance 
usually incurs a fitness cost in bacteria (Andersson & Levin 1999; Andersson 2003; 
Bjorkman & Andersson 2000; Gillespie 2001; Kanai et al. 2004; Levin et al. 2000; 
Maisnier-Patin & Andersson 2004; Normark & Normark 2002; Sander et al. 2002). 
Antibiotic-resistant bacteria frequently acquire compensatory mutations to avoid a fitness 
cost and maintain competitiveness with parent sensitive strains (Andersson 2006). 
However, some resistance-conferring mutations in bacteria incur very little fitness cost, 
none at all, or even enhanced fitness (Luo et al. 2005; Sander et al. 2002; Spratt 1996).  
 Using delicately designed experiments, Luo et al. (2005) recently demonstrated 
that the FQ-resistant Campylobacter do not show a fitness cost in vivo and are 
ecologically competitive in the colonization of chickens even in the absence of antibiotic 
selection pressure. When separately inoculated into chickens, sensitive and resistant 
strains, derived from the same parent strain, showed similar levels of colonization. The 
resistance was persistent throughout this colonization. However, when both strains were 
co-inoculated into the same chicken host, the resistant strain was able to outcompete the 
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sensitive strain. Specifically, when co-inoculated into chickens, the FQ-resistant strain 
outcompeted the FQ-sensitive strain, completely replacing the FQ-sensitive strain in just 
3 days, and the specific resistance-conferring mutation did not disappear after prolonged 
colonization in vivo (Luo et al. 2005). This enhanced fitness was the result of a single 
point mutation in gyrA, instead of compensatory mutations, as evidenced by similar 
findings using isogenic gyrA mutants together with parent FQ-sensitive strain (Luo et al. 
2005).  Fluoroquinolone-resistant Campylobacter have been shown to be competitive 
with FQ-sensitive strains in vivo, displaying similar levels of colonization. 
Fluoroquinolone-resistant Campylobacter have been cultured from farms where FQ 
usage had been discontinued (Luangtongkum et al. 2006; Pedersen & Wedderkopp 2003; 
Price et al. 2005). Fluoroquinolone and macrolide- resistant Campylobacters were found 
on organically and intensively-reared chickens purchased from retail outlets 
(Soonthornchaikul et al. 2006). These results indicate that FQ resistance-conferring 
mutations in Campylobacter are stable, and the resistant strains can persist even in the 
absence of antibiotic selection pressure, presenting an unusual problem. Humans infected 
with FQ-resistant Campylobacter have had prolonged diarrhea and hospitalization, and 
increased risk of complications in comparison to humans infected with FQ-sensitive 
Campylobacter (Nelson et al. 2004), and this might be attributed to increased virulence 
resulting from enhanced fitness of the FQ-resistant Campylobacter. Other studies also 
showed that in comparison with FQ-sensitive Campylobacter, infections with FQ-
resistant Campylobacter have resulted in prolonged illness (Engberg et al. 2004) and 
increased risk of adverse health events (invasive disease or death within 90 days) (Helms 
et al. 2005). 
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 Little information exists concerning fitness cost and stability of macrolide 
resistant Campylobacter. A recent study on the stability of erythromycin-resistant 
Campylobacter with mutations in 23S rRNA gene (corresponding to E. coli numbers 
A2059G, A2058C, and A2058G), revealed that the A2059G and A2058C mutations were 
stable after 15, 35, and 55 passages on MH agar plates (Gibreel et al. 2005). Because 
Campylobacter resistance to macrolides is on the rise, stability of macrolide resistance in  
Campylobacter should be thoroughly investigated to develop effective farm-based 








 Campylobacter jejuni is recognized as a leading cause of human gastrointestinal 
enteritis worldwide (Gibreel et al. 2005; Nachamkin et al. 2000). The majority of 
Campylobacter infections involve diarrhea and abdominal pain, although Campylobacter 
is also associated with Giullain- Barré syndrome, an acute demyelinating disease that can 
result in respiratory compromise and death (Moore et al. 2005; Nachamkin et al. 1998). 
In the United States, the estimated number of cases of campylobacteriosis exceed 2 
million per year (Friedman et al. 2000; Mead et al. 1999). The medical and production 
costs associated with Campylobacter infections are estimated at 1.5 to 8 billion dollars 
each year in the United States (Buzby et al. 1997). Most cases of campylobacteriosis are 
self- limiting, but antimicrobial treatment is often necessary for severe, prolonged, or 
systemic cases, or cases in immunocompromised patients.  
In parallel to its increased prevalence, Campylobacter is increasingly resistant to 
antibiotics including Fluoroquinolone (FQ) and macrolide antibiotics, the drugs of choice 
for treating human Campylobacter infections  (Altekruse et al. 1999; Engberg et al. 
2001). FQ antibiotics are losing their effects on Campylobacter because this pathogen has 
become highly resistant to FQ’s. Therefore, erythromycin (Ery), a macrolide antibiotic, 
has been considered the best choice for treating human Campylobacter infections (Allos 
2001).  Unfortunately, Campylobacter resistance to macrolides is also on the rise and this 
class of antibiotics could eventually lose effectiveness against Campylobacter (Engberg 
et al. 2001; Smith et al. 2007). To develop effective measures to control and prevent the 
spread of macrolide-resistant Campylobacters, the mechanisms of macrolide resistance in 
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Campylobacter are critical to understand, but still are not clear. 
Campylobacter species colonize the intestinal tract of wild and domestic animals 
(Nesbit et al. 2001). Most human Campylobacter infections are associated with 
consumption of undercooked poultry meat, as well as unpasteurized milk and untreated 
water (Friedman et al. 2000). Epidemiologic studies have revealed poultry as the major 
reservoir of Campylobacter (Corry & Atabay 2001; Jacobs- Reitsma 1997). Macrolide 
usage in food producing animals is considered to be a major factor influencing the 
emergence of erythromycin-resistant (EryR) Campylobacter (Gibreel & Taylor 2006). 
However, the direct impact of macrolide usage on erythromycin resistance development 
has not been formally determined in experimental systems until recent examination on 
the dynamics of Campylobacter populations in chickens treated with a tylosin, a 
macrolide antibiotic (Lin et al. 2007). Exposure of chickens to therapeutic doses of 
tylosin did not select for EryR mutants in the treated birds. However, when tylosin was 
given to the chickens in feed at a growth-promoting dose, EryR mutants emerged in the 
birds after prolonged exposure to the antibiotic (Lin et al 2007). Specifically, the 
chickens inoculated with a sensitive C. jejuni strain at 17 days of age started to shed EryR 
mutants on day after inoculation (DAI) 17 in response to long-term exposure to growth 
promoter tylosin; but all EryR mutants only showed low-level Ery resistance with MIC 
ranging from 8 to 16 µg/ml. Interestingly, when chickens were inoculated with the same 
Ery sensitive C. jejuni strain at 3 days of age, EryR mutants were only detected in the 
chickens on DAI 31 and 38 but not in chickens at DAI 17, and 24; majority of EryR 
mutants displayed high-level Ery resistance (MIC > 512 µg/ml).  Although these findings 
provide compelling evidence that long-term use of macrolide as a growth promoter 
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selects for the emergence of EryR Campylobacter in chickens, the length of exposure time 
to macrolide seems not the only factor contributing to the emergence of Ery resistance in 
Campylobacter. 
 The stability of the resistant phenotype is a key parameter influencing the 
development and transmission of antibiotic resistance (Andersson 2006). In many 
bacterial species, antibiotic resistance confers a reduction in bacterial fitness and thus 
antibiotic resistance phenotype is not stable in the absence of antibiotic selection pressure 
(Nachamkin et al. 2000). However, distinct from other bacteria, FQ resistance in 
Campylobacter is very stable and FQ-resistant mutants do not show a fitness cost in vivo 
and are ecologically competitive in the colonization of chickens even in the absence of 
antibiotic selection pressure (Luo et al. 2005). The stability of Ery resistance in 
Campylobacter is still largely unknown. To develop effective farm-based strategies to 
prevent and control emergence and spread of Ery resistant Campylobacter, in vitro and in 
vivo stability of  EryR C. jejuni mutants with different levels of Ery resistance should be 
thoroughly investigated.   
 Significant progress has been made in elucidating molecular mechanisms of 
macrolide resistance in Campylobacter.  Modifications of the ribosomal target site and 
active efflux are the major mechanisms that confer Campylobacter resistance to 
macrolides (Engberg et al. 2001; Trieber & Taylor 2000; Lin & Martinez 2006).  
However, previous studies on the mechanisms of macrolide resistance in Campylobacter 
either focused on the comparison of isolates from various origins or examined macrolide 
resistant mutants selected  in vitro, greatly limiting the interpretation of association of 
specific molecular mechanisms with acquired Ery resistance and limiting elucidation of 
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macrolide resistance development in vivo in Campylobacter (Cagliero et al. 2006b; 
Mamelli et al. 2005). Examination of in vivo- as well as in vitro-selected macrolide 
resistant mutants that are all derived from the same parent sensitive strain would greatly 
improve our understanding on the molecular basis and development of  macrolide 
resistance in Campylobacter.   
Based on this published information and our previous work on antibiotic 
resistance in Campylobacter, we speculate that length of exposure to growth promoter 
tylosin and other in vivo factors affect the dynamics of emergence of  EryR 
Campylobacter mutants. Different molecular mechanisms together contribute to the 
stability and level of Ery resistance in C. jejuni. To test these hypotheses and move 
towards the goal of controlling macrolide resistance in Campylobacter, we pursued the 
following three specific objectives: 
 
1. Determine if long-term exposure of low-level EryR C. jejuni to growth promoter 
tylosin selects for high-level EryR mutants using chicken model system. 
2. Determine in vitro and in vivo stability of the macrolide-resistant phenotype in 
Campylobacter. 
3. Determine the molecular mechanisms of macrolide resistance in C. jejuni mutants 
selected in vitro and in vivo. 
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3. MATERIALS AND METHODS 
 
 
Bacterial Strains and Culture Conditions 
 The key C. jejuni strains used in this study are listed in Table 1. Campylobacter 
jejuni NCTC 11168 is an Ery-sensitive strain whose whole genome sequence has been 
completed and published (Parkhill et al. 2000). NCTC 11168 was purchased from ATCC 
(Cat. No 700819).  The NCTC 11168 was used as a parent strain for in vitro selection of 
macrolide resistant mutants in this study.  The NCTC 11168-derived EryR mutants 
isolated from chickens (Lin et al. 2007) were also used in this study. All Campylobacter 
strains used were cultured in Mueller-Hinton (MH) broth or agar, or media containing 
Campylobacter growth supplement and Preston Campylobacter selective supplement 
(Oxoid) when necessary. MH media were supplemented with various concentrations of 
Ery or tylosin when necessary. Strains were grown at 42˚C under microaerophilic 
conditions using CampyGen gas pack (Oxoid) in enclosed jars.  
 
 
Antibiotic susceptibility test 
 Minimum Inhibitory Concentrations (MICs) were determined using the standard 
agar dilution method as recommended by the CLSI (Formerly NCCLS) (CLSI, 2006). C. 
jejuni ATCC 33560 was used as a quality control strain and the quality control range of 
Ery MIC is 1-4 µg/ml when incubated at 42˚C for 24 hours. Erythromycin stock solutions 
of concentration 25 mg/ml in 100% ethanol were stored at -20˚C. To prepare plates for 
MIC test, Ery stock solution was vortexed vigorously and diluted to 5.12 mg/ml (highest 
concentration) and subsequently diluted two-fold with sterile dd H20 until a final 
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concentration of 0.005 mg/ml was obtained. Two-ml of desired concentration of Ery and 
1 ml of defibrinated sheep blood (Cleveland Scientific, Cleveland, OH) were added in 17 
ml agar deep for preparing agar dilution plates with 11 concentrations ranging from 512 
µg/ml to 0.5 µg/ml. Plates with Ery concentration of 0 µg/ml were made with dd H20 in 
place of Ery and were used as positive control. To prepare inoculum, well-isolated C. 
jejuni colonies from a fresh agar plate (grown at 42oC for 24 hrs) were suspended in MH 
broth to a turbidity equivalent to that of a 0.5 McFarland standard using VITEK 
Colorimeter (bioMerieux, Inc., Durham, NC). Agar dilution test was performed using 
Cathra Replicator System (Oxoid).  The growth and end points were monitored following 
24 hr of microaerophilic incubation at 42oC. According to the new breakpoints 
recommended by CLSI (CLSI, 2006), Ery MIC ≤8 μg/ml and ≥ 32 μg/ml are considered 




In vitro selection of macrolide-resistant mutants 
Erythromycin (SIGMA) or tylosin tartrate (MP Biomedicals) was used as 
selective agent for selecting spontaneous macrolide-resistant mutants in vitro. Briefly, 
100 μl of wild-type Ery-sensitive NCTC 11168 cultures were plated on MH plates and 
grown overnight at 42˚C under microaerophilic conditions.  The fresh cells were then 
harvested from plates using sterile MH broth.  Cell suspension were then plated on 
increasing concentrations of erythromycin and tylosin (4- to 16-fold the initial MIC of 
NCTC 11168). Following 3-5 days incubation under microaerophilic conditions at 42˚C, 
single macrolide resistant colony on selective plates were selected, cultured in MH broth 
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and stored at -80 ˚C.  The Ery-resistant and tylosin-resistant mutants obtained from the 
first round of selection were grown in MH broth containing sublethal concentrations of 
Ery and tylosin, respectively, and then plated on selective plates again for selecting 
mutants with higher level of resistance.  If needed, the procedure was repeated to obtain 
high level macrolide resistant mutants.  All in vitro-selected mutants were subjected to 
MIC test using standard agar dilution method as described above.  In addition, genomic 
DNA was prepared from each mutant and used for PCR amplification and sequence 
analysis of 23S rDNA and ribosomal proteins L4 and L22 genes as detailed below.  
 
Polymerase Chain Reaction (PCR) 
 PCR was performed to analyze the sequences of domain V of the 23S rRNA 
genes, ribosomal proteins L4 and L22 genes, and major outer membrane protein gene 
cmp in C. jejuni.  All primers used for PCR are described in Table 2. PCR was performed 
with a total volume of 50µl containing 1µl of 10 mM concentration of each of the 
deoxynecleoside triphosphates, 5µl of  Mg2+-free thermophilic DNA polymerase 10X 
buffer, 5µl of 25mM MgCl2, 2µl of forward primer (5 pmol/µl), 2µl of reverse primer (5 
pmol/µl), 2.5µl of DNA template, 32µl of dd H20, and 0.5µl of Taq DNA polymerase 
(2.5 U).  Cycle for all reactions was 95˚C for 5 minutes followed by 33 cycles of: 95˚C 
for 30 seconds for denaturation, 50˚C for 30 seconds for annealing, followed by 72˚C for 
1 minute for extension. In all PCR reactions, boiling samples were used as DNA 
templates. Briefly, cultures were grown in MH broth at 42˚C for 48 hours under 
microaerophilic conditions. One ml of C. jejuni cells were centrifuged for 3 min at 
10,000 x g and pellet was suspended in 100µl sterile ddH20.  The tube containing cell 
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suspensions was placed in boiling water for 10 minutes, followed by centrifugation for 3 
minutes at 10,000 x g. Seventy µl of the supernatant was carefully transferred to a clean 
tube and used as a DNA template for PCR. The PCR products were run together with 1 
kb DNA ladder (Promega) in 1% agarose gel at 100 constant volts for 30 minutes. The 
gel was stained by ethidium bromide and digital photographs of gels were taken using 
FluoChem 5500 digital imaging system (Alpha Innotech).  
 
 
Sequence Analysis  
 PCR products were purified using QIAquick PCR Purification Kit (Qiagen). 
Purified products were sequenced using ABI 3730 DNA Sequencer at UTK Molecular 
Core Facility. Sequences were aligned suing NCBI BLAST software at NCBI website 
(http://www.ncbi.nih.gov/blast/bl2seq/wblast2.cgi) and mutations identified. 
 
 
Insertional mutagenesis of cmeB gene 
 Isogenic cmeB mutants of various Campylobacter jejuni isolates were constructed 
using natural transformation. Wild-type strain NCTC 11168 or its Ery-resistant 
derivatives selected in vitro or in vivo was spread on MH agar plates, followed by 
incubation at 42° C for 48 hours. Cells were harvested with MH broth and adjusted to the 
approximate concentration of 3 x 109 CFU/ml. 500μl of C. jejuni cell culture was added 
to 15ml tubes containing 1ml MH agar. The tubes were incubated 3 hours. Following 
uncubation, 5μl of C. jejuni 9B6 genomic DNA was mixed with 500μl of C. jejuni cells 
by pipetting. Tubes were again incubated for 3 hours. To select transformants, cultures 
were spread on MH plates containing kanamycin 30μg/ml and incubated 48 hours. All 
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incubation was performed under microaerophilic conditions at 42° C.  
 
 
Exposure of low-level Ery resistant Campylobacter mutants to subtherapeutic dose 
of tylosin in chickens 
 Two independent experiments were conducted in chickens using tylosin at the 
dose used for growth promotion. In each experiment, day-old broiler chicks (gift from 
commercial company Hubbard Hatchery, Pikeville, TN) were randomly assigned to two 
groups (9-10 per group). All birds were placed in sanitized wire cages with unlimited 
access to feed and water. In the first experiment, chickens in the control group received 
nonmedicated feed. Chickens in the treatment group received the complete feed 
supplemented with tylosin (Elanco Animal Health). All feed was prepared by the feed 
mill at Johnson Animal Research and Teaching Unit. Medicated feed was prepared in 
accordance with the label for preparation of medicated feed used for growth promotion of 
chickens to obtain a final concentration of 50 mg/kg. To confirm that the birds were 
Campylobacter-free, on day 12 (prior to inoculation with C. jejuni), sterile swabs were 
used to take cloacal swab samples from each bird. Swabs were immediately placed in 
small sterile tubes containing 1 ml MH broth. Tubes were briefly vortexed and 100 µl of 
each sample spread on MH plates containing growth and selective supplements, and 
plates were incubated at 42˚C under microaerophilic conditions for 48 hours. All birds 
were Campylobacter-free prior to inoculation. At 15 days of age, all birds were 
inoculated with approximately 107 CFU of fresh C. jejuni DC2 (Ery MIC= 32µg/ml; 
Table 1) culture via oral gavage. Cloacal swabs were then collected on 17, 22, 29, 36, 43, 
and 50 days of age. Samples from each bird were were diluted serially, and each dilution 
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was spread onto two different types of MH plates: one containing Campylobacter-
specific growth and selective supplements (SR084E and SR117E; Oxoid) to recover the 
total Campylobacter populations, and the other containing 8 µg/ml Ery (for control group) 
or 128µg/ml Ery (for treatment group) in addition to the same growth and selective 
supplements to recover the Campylobacter populations that were considered not 
susceptible to Ery.  Campylobacter colonies were counted following 48 h of incubation at 
42oC under microaerophilic conditions. Individual colonies were also collected from 
selective plates for each chicken and was used for MIC testing. Representative isolates 
were also selected for PCR amplification and sequence analysis of 23S rDNA and rplD 
and rplV genes encoding ribosomal proteins L4 and L22. Poultry is usually 
Campylobacter-free for the first 2-3 weeks of age in commercial conditions. Therefore, 
inoculating birds with C. jejuni at day 15 in this study mimics commercial broiler 
production conditions.  
In the second experiment, chickens were randomly assigned to two groups and 
chickens in both group received the feed supplemented with tylosin with a final 
concentration of 50 mg/kg feed. At 15 days of age, each chicken within each group was 
either inoculated with approximately 107 CFU of fresh C. jejuni DC2 (Ery MIC= 32µg/ml) 
or DC26 (Ery MIC= 64µg/ml; obtained from the first chicken experiment) via oral 
gavage. Cloacal swabs were collected on 20, 34, and 48 days of age. Representative 
isolates from each bird on each sample day were subjected to differential plating, MIC 




In vitro stability of Ery resistance 
 One low-level Ery resistant mutant (DC2; Ery MIC= 32µg/ml) and two high-level 
Ery resistant mutants (DC3 and DC6; Ery MICs> 512µg/ml) (Table 1) were used for in 
vitro stability test and all these mutants are chicken isolates derived from the same parent 
strain NCTC 11168 (Lin et al, 2007). Experimental design is outlined in Figure 1. To 
perform in vitro stability test, all mutants were inoculated in antibiotic-free MH broth and 
grown in microaerophilic conditions at 42˚C. Every 48-72 hours, 10 µl of each culture 
was subcultured in 4 ml fresh MH broth (1:400 dilution) for a total of 33 passages. 
Following passages 10, 20, and 33, the cultures were serially diluted (10-fold dilution) in 
MH broth and plated on both MH agar plates and MH agar plates supplemented with Ery 
at final concentration of 8 µg/ml (DC2) or 128 µg/ml (DC3, DC6). Plates were incubated 
at 42˚C under microaerophilic conditions for 48 hours. Total numbers of colonies on each 
type of plate were counted and compared. In addition, following passage 33 differential 
plating, 10 colonies for each mutant were randomly chosen from MH agar plates and 
were subjected to Ery MIC test using standard agar dilution method as described above.   
 
In vivo stability of Ery resistance using chicken model system 
 Day-old broiler chicks (gift from commercial company Hubbard Hatchery, 
Pikeville, TN) were randomly assigned to two groups (12-13 birds per group). All birds 
were placed in sanitized wire cages with unlimited access to feed and water. Feed was 
nonmedicated feed without any antibiotic additives and was prepared by the feed mill at 
Johnson Animal Research and Teaching Unit. At 3 days of age, all birds were inoculated 
with approximately 107 CFU fresh C. jejuni culture via oral gavage. Chickens in group A 
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were inoculated with C. jejuni DC2, a low-level Ery resistant C. jejuni mutant (MIC= 
32µg/ml) that was obtained from previous chicken study (Lin et al 2007).  In group B, all 
chickens were inoculated with a highly EryR mutant DC6 (MIC> 512µg/ml) that was also 
obtained from previous chicken study (Lin et al 2007). Cloacal swabs were then collected 
on day 12, 22, 38, and 47. Isolation of Campylobacter and differential plating for 
enumerating the proportion of the mutant colonies were conducted as described above.  
Samples from group A were subjected to differential plating on MH plates supplemented 
with growth and selective supplements, and with or without Ery 8µg/ml. Samples from 
group B were subjected to differential plating on MH plates supplemented with growth 
and selective supplements, and with or without Ery 128µg/ml. Representative isolates 
from each chicken were selected for Ery MIC test. Selected isolates were also subjected 
to PCR amplification and sequence analysis of 23S rDNA and rplD and rplV genes 
encoding ribosomal proteins L4 and L22.  To confirm that C. jejuni strain used for 
inoculation was the same strain collected from cloacal swabs, major outer membrane 
protein gene cmp (MOMP), a good target for molecular typing in Campylobacter (Huang 
et al. 2005), was PCR amplified in the input strain and a representative output isolates 
and subjected to sequencing analysis. MOMP gene sequencing revealed no difference 
between input strain and output isolates. 
 
Detection limit and statistical analysis 
In all chicken experiments, the detection limit of the plating methods is 
approximately 100 CFU/g of feces.  Student’s t test was used to examine the significance 
of differences in Campylobacter colonization levels (log transformed CFU/g feces) at 
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Colonization of EryR mutants in response to tylosin treatment. 
In the first chicken experiment in which C. jejuni DC2 was used to inoculate  
chickens either receiving medicated or nonmedicated feed, all chickens, including the 
ones with the medicated feed,  were successfully colonized by C. jejuni DC2 on d 17 
(two days after inoculation) (Figure 2). The shedding level of Campylobacter in feces 
was consistently higher (up to 1.8 log10 units) in the chickens given nonmedicated feed 
than in those given tylosin-containing feed, except that on d 50 the shedding levels of C. 
jejuni for the nonmedicated group was slightly lower (but the difference was not 
statistically significant: P > 0.05) than those from medicated group (Figure 2).   
In the second chicken experiment, chickens were assigned to two groups that 
were inoculated with either low-level EryR C. jejuni DC2 (Ery MIC= 32µg/ml) or DC26 
(Ery MIC= 64µg/ml) but all chickens were treated with medicated feed throughout the 
study.  All chickens were successfully colonized by DC2 or DC26 at 20 days of age (5 
days after inoculation) (Figure 3).  Both groups of chickens displayed similar shedding 
levels of Campylobacter throughout the study although DC2 seemed colonize slightly 
better than DC 26 on day 20 (Figure 3).  
Representative C. jejuni isolates derived from chickens were analyzed by PCR 
(for the MOMP gene) (Figure 4) and subsequent sequence analysis, which revealed that 




Effect of prolonged low dose tylosin treatment on the emergence of high-level EryR 
C. jejuni in chickens 
 
In the first experiment, day-old broiler chicks were placed in two groups, 
receiving feed supplemented with tylosin at a concentration of 50mg/kg (treatment 
group), or nonmedicated feed (control group). After inoculation of chickens with DC2 at 
15 days of age, cloacal swabs collected every 2-7 days and used to determine the 
percentage EryR populations of C. jejuni, and levels of Ery resistance for both groups. In 
control group, all isolates obtained from chickens at 29 days of age became susceptible to 
Ery as determined by MIC test (Figure 5, Table 3), which was also confirmed by 
differential plating method. Each chicken in the treatment group consistently shed EryR C. 
jejuni throughout the study (Figure 5, Table 3). By day 29, and every sample day 
thereafter, mutants with Ery MIC of 64 µg/ml were isolated in the treatment group (Table 
3). However, no high-level EryR organisms were selected throughout the study. These 
results suggest that low-level Ery resistance in C. jejuni is not stable in the absence of 
antibiotic selection pressure and long-term exposure of C. jejuni to low-dose tylosin may 
not be enough for developing high-level Ery resistance in C. jejuni. 
To further confirm the finding from above chicken experiment, DC2 together with 
its new derivative DC 26 (Ery MIC = 64 µg/ml; from above chicken study) were used to 
challenge chickens receiving tylosin-containing feed (50 mg/ml).  As shown in Table 4, 
regardless of the mutants used for inoculation, none of chickens shed high-level EryR C. 
jejuni (MIC > 512 µg/ml) with up to 33 days continuous tylosin treatment, which is also 
consistent with differential plating result. However, in the group inoculated with C. jejuni 
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DC2, a mutant with Ery MIC of 256µg/ml was obtained on day 48 (Table 4) while in the 
group inoculated with DC26 mutants with MIC of 128µg/ml were selected on each 
sampling day (Table 4). Together, these findings confirmed the results from the first 
chicken experiment and indicated that long-term antibiotic selection pressure should 
work together with other factors to select high-level Ery resistance in Campylobacter.  
  
In vitro stability of Ery resistance in C. jejuni 
 C. jejuni strains DC2 (Ery MIC= 32µg/ml) and two high-level EryR mutants DC3 
and DC6 (Ery MIC> 512µg/ml) were used for in vitro stability test. All these three EryR 
mutants are chicken isolates derived from NCTC 11168 in a previous chicken experiment 
(Lin et al. 2007). As shown in Figure 6, more than 60% of DC2 populations could still be 
selected on MH plates containing 8 µg/ml Ery after 10 passages while all DC3 as well as 
DC6 populations grew well on MH plates containing 128 µg/ml of Ery. By passage 
number 20 and 33, Ery-resistant populations in DC2 culture were dramatically dropped to 
13% and 7%, respectively (Figure 6). However, both DC3 and DC6 displayed high 
stability after 20 and 33 passage; near100% populations could still be recovered on MH 
plates containing 128 µg/ml of Ery (Figure 6). The differential plating results (Figure 6) 
were also confirmed by Ery MIC tests of representative isolates selected on MH plates 
for passage 33. Majority of DC2 isolates showed Ery MIC of 2µg/ml that is comparable 
with the MIC of wild-type sensitive level. However, all tested DC3 and DC6 had Ery 
MIC> 512µg/ml. Together, these results indicated that high-level Ery resistance (Ery 
MIC > 512µg/ml) in C. jejuni is stable in vitro while low-level Ery resistance is not.  
 
  34
In vivo stability of Ery resistance in C. jejuni 
 Both DC2 and DC6 strains were chosen for in vivo stability test of Ery resistance 
in C. jejuni using chicken model system. At 12 days of age (9 days after C. jejuni 
inoculation), each chicken in both groups was colonized by DC2 or DC6 with average 
colonization level from 3.7 to 4.9 Log10 units (Figure 7). Differential plating showed no 
EryR C. jejuni mutant was detected in DC2-inoculated chickens by day 38 using MH 
selective plates containing 8 µg/ml Ery (Figure 8).  However, high-level Ery resistance 
was maintained throughout the study; approximate 100% of C. jejuni populations from 
chicken inoculated with  DC6 grew on MH selective plates containing 128 µg/ml of Ery 
for the entire study, suggesting high-level Ery resistance is very stable in vivo (Figure 8). 
MIC test of all randomly selected isolates from each individual chickens further 
confirmed these findings (Table 5). For low-level EryR mutant DC2, the instability of 
low-level Ery resistance was also observed in chickens as early as 9 days after 
inoculation (day 12); two of 12 isolates from 12-day-old chicken displayed reduced Ery 
MIC (16 µg/ml) (Table 5).  With further growth of DC2 in chickens without tylosin 
selection pressure, majority of isolates from chickens inoculated with DC2 displayed Ery 
MIC similar to that of wild-type sensitive strain on day 38 and 47f (Table 5). In contrast, 
all isolates from chicken inoculated with DC6 consistently displayed high-level  Ery 
resistance (MIC> 512µg/ml), regardless sampling date (Table 5).  
 
Molecular mechanisms of Ery resistance in mutants selected in vitro and in vivo 
 Thirty in vitro-selected and thirty three in vivo-selected EryR C. jejuni mutants (all 
NCTC 11168 derivatives) were subjected to PCR amplification of 23S rRNA gene and 
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rplD and rplV genes encoding ribosomal proteins L4 and L22, respectively (Figure 9). 
The sequences of these PCR products were aligned to corresponding sequence of parent 
strain NCTC 11168 to identify specific mutations occurred in ribosome.  
With respect to 23S rRNA gene, all high-level EryR isolates selected in vitro 
(JL287-289) displayed an A→C point mutation at position 2074 (Table 6) while all high-
level EryR isolates selected in vivo (DC3, 6, 9, 31, 32, 33) displayed a different point 
mutation at the same position (A2074G ) (Table 7). According to sequence results, it 
appeared that A2074C mutation was present in two of the three copies of the 23S rRNA 
gene in mutants selected in vitro, because the sequence chromatogram showed double 
peaks in the same position where the C peak was two times higher than the A peak 
(Figure 10). Regardless of selection environment, none of EryR mutants with Ery MIC ≤  
512µg/ml displayed point mutation in the domain V of the 23S rRNA genes (Table 6 and 
7).   
Changes in ribosomal protein L4 were not detected in mutants selected in vitro 
(Table 6) and were only observed in majority of low-level EryR isolates selected in vivo 
(22 of 25 isolates, MIC range 8- 64µg/ml) (Table 7). Specifically, these mutants showed 
a G→D change either at positions 74 or 57 (Table 7, Figure 12). The G74D modification 
in ribosomal protein was stable in the presence of continuous tylosin selection pressure 
(DC21-27 in Table 7).  However, in the absence of tylosin selection pressure in feed, the 
Ery MIC of randomly selected isolates decreased (DC28-30), consistent with the loss of 
specific G74D point mutation in L4 protein (Table 7).   
Modification in ribosomal protein L22 was only observed in EryR mutants 
selected in vitro but not in the mutants selected in vivo (Table 7).  Specifically,  a 3-
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amino acid insertion (TSH) at position 98 in protein L22  was observed in isolates 
selected in vitro with wide Ery MIC range from 32 to 512 µg/ml (Table 6, Figure 11). It 
seemed that use of specific selective agent (Ery or tylosin) did not affect development of 
Ins98TSH modification in L22 protein (Table 6).   
The different mutations in EryR mutants were summarized in Table 8. 
Interestingly, some of EryR mutants, either selected in vivo or selected in vitro, did not 
display any mutations in the sequenced three gene targets (Table 6-8).  Such mutants 
include four in vivo-selected mutants (DC1, DC4, DC11, and DC29) with  Ery MIC 
ranging from 4 to 64 µg/ml  (Table 7 and 8) and 50% in vitro-selected mutants with Ery 
MIC ranging from 8-128 µg/ml  (Table 6 and 8).  
 
Contribution of CmeABC efflux pump to the acquired Ery resistance 
To determine the contribution of the CmeABC efflux pump to the acquired Ery 
resistance, CmeABC mutation was transferred to selected EryR mutants and Ery MIC of 
each isogenic CmeB mutant was measured by standard agar dilution method. As shown 
in Table 9, regardless the presence of specific mutation in 23S rRNA gene (DC32, JL287, 
JL288), in L4 protein (DC22, DC27), in L22 protein (Jl290, JL301, JL303), or absence of 
any mutation (JL283, JL284), inactivation of cmeB dramatically reduced Ery MIC (8 – 
1024 folds) when compared to its parent strain (Table 9), indicating that CmeABC works 
synergistically with other mechanisms to maintain high-level and low-level Ery 






The results of this study reveal several unique features with respect to macrolide 
resistance development, stability, and associated molecular mechanisms in 
Campylobacter jejuni. First, exposure time to subtherapeutic level of tylosin is not a sole  
factor contributing to emergence of highly EryR Campylobacter. Prolonged exposure of 
low-level EryR C. jejuni (MIC = 32 or 64 µg/ml) to growth promoter tylosin did not 
select for high-level  EryR C. jejuni (Table 3, 4).  Second, high-level Ery resistance (MIC 
>512 μg/ml) displayed remarkably stability in vitro and in vivo.  (Figures 6, 8, Table 5). 
However, the low-level Ery resistance (MIC = 32 μg/ml) was not stable in vitro and 
majority of C. jejuni were sensitive to Ery after 20 passages (Figure 6).  The instability of 
low-level Ery resistance was also observed in chickens as early as 9 days post inoculation 
and EryR mutants were rarely isolated 35 days post inoculation (Table 5, Figure 8).  Third, 
sequencing analysis of 23S rDNA, L4 and L22 genes revealed that molecular 
mechanisms contributing to Ery resistance in C. jejuni differ between high-level and low-
level resistant isolates and between isolates selected in vivo and in vitro. (Figures 
10,11,12, Tables 6,7,8, 9). Fourth, mutation in CmeABC efflux pump drastically reduced 
MIC of Ery for EryR mutants selected in vitro and in vivo, indicating CmeABC worked 
synergistically with other mechanisms to confer Ery resistance in C. jejuni (Table 9). 
Together, these findings indicated that C. jejuni utilize complex and different 
mechanisms to develop Ery resistance in vitro and in vivo  
Recently, Lin et al., (2007) conducted a study to examine the development of Ery 
resistance in C. jejuni in chickens upon exposure to growth promoter tylosin. When 
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tylosin was given to the chickens in feed at a growth-promoting dose, EryR mutants 
emerged in the birds after prolonged exposure to the antibiotic. In experiment 1, when 
chickens were inoculated with Ery sensitive C. jejuni strain at 3 days of age, EryR 
mutants were finally detected in the chickens on 31 days after inoculation (DAI 31) and 
DAI 38 but not in chickens at DAI 17, and 24; majority of EryR mutants from DAI 31 
and 38 displayed high-level Ery resistance (MIC > 512 µg/ml).  In experiment 2, the 
chickens inoculated with the same sensitive C. jejuni strain at 17 days of age started to 
shed EryR mutants at DAI 17; but all EryR mutants only showed low-level Ery resistance 
with MIC ranging from 8 to 16 µg/ml.  Further 1-week exposure did not promote 
emergence of any mutants with higher level Ery resistance at DAI 24.  Although these 
findings indicate that long-term use of tylosin as a growth promoter selects for EryR 
Campylobacter in chickens, it is intriguing why highly Ery-resistant Campylobacter 
emerged without pre-emergence of low-level EryR mutants at DAI 24 in experiment 1.  Is 
the length of exposure time a major factor contributing to emergence of high-level EryR C. 
jejuni? Does emergence of highly EryR Campylobacter mutants require stepwise 
accumulation of various identified mutations in ribosome? To address these issues, in this 
study, we first conducted two chicken experiments to determine if long-term exposure of 
two low-level EryR Campylobacter mutants results in emergence of high-level Ery 
resistant mutants.  The findings from this study (Table 3 and 4) strongly suggest that 
exposure time is not a sole factor selecting for high-level Ery resistant C. jejuni. Some 
unknown factors in conjunction with continuous antibiotic selection pressure may 
determine the rate of occurrence of highly EryR Campylobacter.  For example, gut 
microflora may play an important role. Campylobacter species have an exceptional 
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ability for taking up heterologous DNA. Thus, interspecies exchange of genetic material 
between Campylobacter and other bacterial flora (e.g. macrolide resistant populations) in 
intestine may lead to the emergence of Ery resistant Campylobacter.  Other factors, such 
as anatomy, physiology, and specific tissue concentration of tylosin, may also affect the 
rate of emergence of high-level  EryR Campylobacter.   
Sequence analysis revealed that all high-level EryR mutants (MIC >512 μg/ml) 
selected in vivo displayed the specific A2074G mutation in 23S rRNA gene while 
specific mutations in L4 (G74D or G57D) were widely found in low level EryR mutants 
(Ery MIC = 8-64 μg/ml) selected in vivo (Table 7).  No single EryR mutant displayed 
mutations in both 23S rRNA gene and L4 protein, which suggest that specific mutations 
in L4 contribute to low-level Ery resistant but are not essential for further development of 
high-level resistance in C. jejuni in chicken. Similarly, no single in vitro-selected EryR 
mutant displayed mutations in both 23S rRNA gene and L22 protein either (Table 6). 
This finding is also consistent with recent in vitro study (Cagliero et al. 2006b) and also 
suggests that 23S rRNA gene mutation and change in L4 protein or L22 protein may not 
co-exist in EryR Campylobacter. However, it does not mean that low-level Ery resistance 
is not required for developing high-level Ery resistance. We have obtained some EryR 
mutants that do not have any mutations in domain V of the 23S rDNA, L4 or L22 genes, 
such as DC1, DC4, and DC11 selected in vivo,  and JL283-289 selected in vitro (Tables 
6,7,8), The Ery resistance mechanisms in these mutants needs to be determined in the 
future and the novel mechanisms required for low-level resistance in these mutants may 
make C. jejuni survive better under selection pressure and facilitate the development of 
high-level Ery resistance in Campylobacter.   
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Campylobacter jejuni has displayed unique feature with respect to the fitness and 
stability of antibiotic resistance (Luo et al. 2005; Zhang et al. 2003). Chromosomal 
mutation- or plasmid acquisition-mediated antibiotic resistance generally incur a fitness 
cost in bacteria (Andersson & Levin 1999; Levin et al. 2000). However, Luo et al (2005) 
demonstrated that FQ resistance in Campylobacter is very stable and FQ-resistant 
mutants do not show a fitness cost in vivo. Interestingly, FQ resistant Campylobacter 
mutants are ecologically more competitive in the colonization of chickens than their FQ-
sensitive parent strain even in the absence of antibiotic selection pressure (Luo et al. 
2005). Does Ery resistance in Campylobacter have the same distinct feature? It has been 
observed that high-level Ery resistance that is associated with A2075G and A2074C 
mutations in 23S rRNA in Campylobacter was  stable in vitro in the absence of macrolide 
selection pressure (Gibreel et al. 2005; Kim et al. 2006). In this study, both in vitro and in 
vivo experiments provided compelling evidence that low-level Ery resistance is not stable 
in C. jejuni while high-level Ery-resistant mutants displayed remarkably stability. The 
phenotype of Ery resistance stability in C. jejuni could be contributed by two factors: 
reverse mutation rate of specific Ery resistance associated mutation (e.g. A2074G in 23S 
rRNA gene) and fitness cost of EryR Campylobacter mutant due to acquisition of specific 
mutation(s). It is technically difficult to assess reverse mutation rate of specific Ery 
resistance associated mutation. However, given the fact that the emergence of 
spontaneous EryR mutants in vitro is at a low frequency in Campylobacter (Lin et al. 
2007), it is likely that in vitro reverse mutation rate is also low. With respect to point 
mutation in 23S rRNA that is associated with high-level Ery resistance, acquisition of 
such mutation either alone or with unknown compensatory mutation(s) may result in little 
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fitness cost. Consequently, the highly EryR C. jejuni mutants may not be outcompeted by 
sensitive strain after successive multiplication either in vitro or in vivo with removal of 
antibiotic selection pressure, leading to high stability or persistence phenotype as we 
observed in this study. In contrast, changes in L4 or L22 may result in increased fitness 
cost in low-level EryR C. jejuni mutants according to our findings in this study. Thus, as 
soon as sensitive C. jejuni emerges in total populations due to the loss of specific 
characterized mutation (e.g. G74D in L4) or other unknown mutation(s), the sensitive 
populations, which display higher fitness than low-level EryR C. jejuni mutants, will 
eventually become dominant.  The randomly selected isolates (DC28-30) from the 47-day 
old chickens that have been inoculated strain DC2 (Ery MIC = 32 ug/ml) and received 
non-medicated feed (Table 7) showed reduced MIC (1-8 ug/ml) with or without specific 
G74D mutation in L4, strongly suggesting that G74D mutation together with other 
uncharacterized mutation(s) contribute to low-level resistance and none of these 
mutations is stable in vivo.  
Previous investigation on the mechanisms of macrolide resistance in 
Campylobacter either focused on the comparison of isolates from various origins or 
examined macrolide resistant mutants selected  in vitro, greatly limiting the interpretation 
of association of specific molecular mechanisms with acquired resistance and limiting 
elucidation of macrolide resistance development in vivo (Cagliero et al. 2006b; Corcoran 
et al. 2006; Gibreel et al. 2005; Kim et al. 2006; Mamelli et al. 2005). Distinct from these 
studies, we examined a panel of in vitro- and in vivo-selected EryR C. jejuni mutants that 
are all derived from the same parent strain C. jejuni 11168.  Sequence analysis and Ery 
MIC test revealed several unique findings with respect to the molecular mechanisms of 
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Ery resistance development in Campylobacter.  First, with respect to high-level Ery 
resistance (MIC > 512 µg/ml), all mutants selected in vivo displayed A2074G mutation 
while all mutants selected in vitro displayed A2074C mutation in 23S rDNA.  Different 
environment (in vitro vs. in vivo) may be a major factor causing such difference.  
However, we cannot rule out the possibility that different selective agents may select for 
different point mutation.  In this study, tylosin was supplemented in feed for selecting 
EryR mutants developed in chicken and erythromycin was used in vitro to select high-
level EryR mutants (JL287-289).  We have made extensive efforts to select high-level 
EryR mutants using tylosin as selective agent in vitro.  However, we failed to obtain high-
level EryR mutants with point mutation in 23S rDNA using tylosin for mutant selection in 
vitro, further suggesting selection pressure resulting from tylosin alone may not be 
enough to promote emergence of high-level EryR C. jejuni mutants.  Second, with respect 
to low- and intermediate-level Ery resistance development, growth environment seems to 
determine specific type of modification in ribosomal protein that confers Ery resistance.  
Although one study (Cagliero et al, 2006b) showed one in vitro-selected EryR C. jejuni 
mutant acquired G74D mutation in ribosomal protein L4, we only identified such 
mutation and another novel mutation G57D in L4 in mutants selected in vivo but not in 
vitro.  Modification in ribosomal protein L22 (TSH98 insertion) was only found in EryR 
mutants selected in vitro with Ery MIC from 32 µg/ml to 512 µg/ml, regardless specific 
selective agent used (tylosin or Ery).  Finally, some of in vivo-selected mutants (DC1, 
DC4, and DC11) and in vitro-selected mutants (JL276-JL279, Jl283-JL286, and JL292-
JL298) do not have any mutations or modifications in domain V of 23S rRNA gene and 
in ribosomal proteins L4 and L22.  Some of these mutants have Ery MIC as high as 128 
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µg/ml  (e.g. JL284-286). Molecular mechanisms of Ery resistance in these isolates need 
to be examined in the future. Taken together, these findings indicated that C. jejuni utilize 
complex and different mechanisms to develop Ery resistance in vitro and in vivo. 
CmeABC efflux pump is widely noted as being linked to macrolide resistance in C. 
jejuni (Lin et al., 2007; Cagliero et al., 2006; Gibreel et al., 2005; Mamelli et al., 2005; 
Martinez and Lin, 2006). In these studies, inactivation of CmeABC by site-directed 
mutagenesis or inhibition of CmeABC by efflux pump inhibitor dramatically reduced Ery 
MIC in wild-type sensitive strains or in Ery-resistant mutants, indicating CmeABC 
contributes to both intrinsic and acquired Ery resistance.  In this study, regardless of the 
presence of specific target mutations in the ribosome, inactivation of CmeB greatly 
reduced the Ery resistance of all EryR isolates (Table 9), indicating that CmeABC 
multidrug efflux pump is a significant player in maintaining the acquired resistance to 
Ery.  In all low-level resistant isolates from in vivo and in vitro studies, inactivation of 
CmeB led to a drastic reduction in Ery MIC to a level that was even below that of the 
wild-type strain. This can be explained by the known role of CmeABC in the intrinsic 
resistance to various antibiotics (Lin et al. 2002).  With respect to three high-level 
resistant isolates (MIC>512μg/ml), inactivation of CmeB led to the decrease of Ery MIC 
to 64 µg/ml in DC32 and JL288 and to 0.5 µg/ml in JL287. It is still unknown why 
inactivation of CmeB in two similar in vitro-selected highly Ery-resistant mutants (JL287 
and JL288) led to different MIC reductions. The mechanism of how CmeABC 
synergistically functions together with other mechanism(s) to confer Ery resistance in 
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Table 1. Key Campylobacter jejuni strains used in this study. 
 
 
























wild-type, Erya sensitive 
 
 
ATCC 33560, quality control strain for MIC testing 
 
cmeB::kan, C. jejuni 81-176 derivative. Also named 
JL30 
 
Ery resistant (MIC = 32µg/ml), NCTC 11168 
derivative isolated from chicken treated with growth 
promoter tylosin 
 
Ery resistant (MIC > 512µg/ml), NCTC 11168 
derivative isolated from chicken treated with growth 
promoter tylosin 
 
Ery resistant (MIC > 512µg/ml), NCTC 11168 
derivative isolated from chicken treated with growth 
promoter tylosin 
 
Ery resistant (MIC= 64µg/ml), isolated from chicken 
inoculated with DC2 and treated with growth 
promoter tylosin 
 





(Lin et al. 2002) 
 
 

























Table 2. PCR primers used in this study. 
 
 









5’- GTA GTT AAA GGT GCA GTA CCA -3’ 
 














5’- GAA TTT GCT CCA ACA CGC -3’ 
 














5’- GTA AAC GGC GGC CGT AAC TA -3’ 
 













5’-ATG AAA CTA GTT AAA CTT AGT TTA-3’ 
 


























Table 3. Erythromycin MICs of C. jejuni isolates from chickens receiving non- 
medicated feed (Control) or feed supplemented with tylosin (50 mg/kg) (Treatment).  
 
 
Chicken group a Day of age Ery MIC (µg/ml) # of isolates 


































































a Each chicken was inoculated with approximately 107 CFU of C. jejuni DC2 (Ery MIC= 








Table 4. Erythromycin MICs of C. jejuni isolates obtained from chickens receiving feed 
supplemented with tylosin (50 mg /kg). 
 
 



































a Each chicken was inoculated with approximately 107 CFU of either C. jejuni DC2 (Ery 
























Table 5. In vivo stability of Ery-resistance in C. jejuni. 
 
 

































12 >512 13 
22 >512 13 
38 >512 13 
 
DC6 (Ery MIC> 512µg/ml) 






















Table 6. Mutations in 23SrRNA and changes in ribosomal protein L22 in C. jejuni 
mutants selected in vitro. 
 
 






































































































































































































































-  no observed mutation  
a A2074C mutation was present in two of the three copies of the 23S rRNA gene. 
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Table 7. Continued. 
 
 


































- no observed mutation 
a from individual chicken receiving medicated feed and inoculated with DC2 in the first 
chicken experiment to determine development of high-level Ery resistance (pages 27- 28)  
b from individual chicken in experiment to determine in vivo stability (page 35) 
c from individual chicken inoculated with DC6 in chicken experiment to determine in 
vivo stability of Ery resistance (page 35). 
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Table 8. Summary of ribosome modifications in Ery-resistant C. jejuni mutants selected  
in vivo and in vitro. 
 
Strain # of 
isolates 






Wild type 1 1 - - - 
6 >512 A2074G - - 
18 8-64 - G74D - 
4 8,16,16,32 - G57D - 
in vivo- 
selected mutants 
4 4,8,8,64 - - - 
3 >512 A2074C - - 
12 32-512 - - Ins98TSH 
in vitro- 
selected mutants 
15 8-128 - - - 
 




























Table 9. Effect of inactivation of CmeABC multidrug efflux pump on the susceptibility 
















1 - - - 0.25 
in vivo- selected mutants 
DC22 32 - G74D - 0.25 
DC27 64 - G74D - 0.25 
DC32 >512 A2074G - - 64 
in vitro- selected mutants 
JL283 64 - - - 0.25 
JL284 128 - - - 0.5 
JL287 >512 A2074C - - 0.5 
JL288 >512 A2074C - - 64 
JL290 32 - - Ins98TSH 0.5 
JL301 512 - - Ins98TSH 0.5 




























*1 swab per chick, MIC and differential plating for each swab 
in vitro test 
 Day of Age  3             10                22               38              47     
 
Oral inoculation:  107 CFU/ chick, 12-13 chicks per group 
                                swab          swab            swab           swab 
Inoculation in MH broth, followed by repeated sub-culturing, 1:400 dilution
                            sample                 sample               sample 
Passage #      0                        10                        20                      33 
*Differential plating for both mutants on each sample day 




































Figure 2.  The shedding level of Campylobacter jejuni DC2 in chickens receiving non-
medicated feed and feed supplemented with growth promoter tylosin (50 mg/kg). 
Each chicken was inoculated with approximately 107 CFU of C. jejuni DC2 (Ery MIC= 
32µg/ml) via oral gavage at 15 days of age. Control chickens received non-medicated 
feed. Treatment chickens received feed supplemented with tylosin (50 mg/kg). Each bar 
represents the mean log10 CFU/g feces +/- standard deviation in each group. Different 
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Figure 3.  The shedding level of Campyobacter jejuni DC2 or DC26 in chickens 
receiving feed supplemented with growth promoter tylosin (50 mg/kg). Each chicken was 
inoculated with approximately 107 CFU of  C. jejuni DC2 (Ery MIC= 32µg/ml) or DC26 
(Ery MIC= 64µg/ml) via oral gavage at 15 days of age. All chickens received feed 
supplemented with tylosin (50 mg/kg). Each bar represents the mean log10 CFU/g feces 









Figure 4. PCR amplification of Campylobacter MOMP gene for sequence analysis. Lane 
1 is 1kb DNA ladder. C. jejuni MOMP gene specific primers were used to amplify 
MOMP gene from inoculated strain, DC26 (Lane 2), and from three randomly selected 
isolates from chicken feces (Lanes 3-5). 
 








































Figure 5. Development of Ery resistance in C. jejuni DC2 in response to prolonged low 
dose tylosin treatment. Each chicken was inoculated with approximately 107 CFU of C. 
jejuni DC2 (Ery MIC= 32µg/ml) via oral gavage at 15 days of age. Control chickens 
received non-medicated feed. Treatment chickens received feed supplemented with 














































Figure 6. In vitro stability of low-level EryR C. jejuni DC2 (MIC= 32µg/ml) and high-
level EryR C. jejuni  DC3 and DC6 (MIC> 512µg/ml). Percentage of EryR population was 





































Figure 7. The shedding level of low-level Ery-resistant C. jejuni DC2 or high-level Ery 
resistant C. jejuni DC26 in chickens receiving non-medicated feed. Each chicken was 
inoculated with approximately 107 CFU of either C. jejuni DC2 (Ery MIC= 32µg/ml) or 
DC6 (MIC> 512µg/ml) at 3 days of age. All chickens received non-medicated feed. Each 
bar represents the mean log10 CFU/g feces +/- standard deviation in each group. Different 
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Figure 8. In vivo stability of low-level EryR C. jejuni DC2 and high level EryR C. jejuni 
DC6. Each chicken was inoculated with approximately 107 CFU of C. jejuni DC2 (MIC= 
32µg/ml) or DC6 (MIC> 512µg/ml) via oral gavage at 3 days of age. Chickens received 
non-medicated feed. Calculation of % Ery resistant mutants is based on MIC testing 















Figure 9. PCR amplification of genes associated with erythromycin resistance in C. 
jejuni: (A) Amplification of 23S rRNA gene using 23S gene specific primers; (B) 
Amplification of full-length ribosomal protein L4 gene (rplD) using rplD specific 
primers; and (C) Amplification of full-length ribosomal protein L22 gene (rplV) using 
























Figure 10.  Sequence chromatogram of mutations in 23S rDNA of highly EryR mutants 











in vivo-selected mutants 


















Figure 11. Sequence chromatogram of mutations in ribosomal protein gene L22 in EryR 


















Figure 12. Sequence chromatogram of mutations in ribosomal protein gene L4 in EryR 
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